Clinical trials: Headache, Migraine
Foramen Ovale, Patent
The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness
The primary objective of this study is to demonstrate the safety and efficacy of the PFX Closure System when utilized for patent foramen ovale (PFO) in patients suffering from cryptogenic stroke (undetermined cause of stroke)…
- Trial name
- NCT00196040
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Cierra
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.
- Trial name
- STRIVE (NCT02456740)
- Testing
- Erenumab
- Where
- 129 sites in United States, Austria and 11 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Healthy
A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants
The main purpose of this study is to compare the amount of lasmiditan that gets into the blood stream and how long it takes the body to get rid of it, when given as a oral-disintegrating (OD) tablet compared to immediate-release…
- Trial name
- NCT04881747
- Testing
- Lasmiditan
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine Disorders
American Migraine Prevention Study
The purpose of this study is to evaluate the use of nutritional supplementation and dietary management for the reduction in frequency, duration, and intensity of migraine headache pain.
- Trial name
- NCT00363506
- Testing
- Serotona Plus and dietary behavior management
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Dynamic Health Resources
Migraine
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in subjects ages 6 to 11 years. Part 1: Approximately 20 weeks (includes screening and double-blind treatment).
- Trial name
- NCT03275922
- Testing
- ZNS
- Where
- 47 sites in United States
- Volunteers
- 374 people
- Sponsor
- Impax Laboratories, LLC
Migraine in Children, Migraine
A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab
The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.
- Trial name
- NCT04537429
- Testing
- Eptinezumab
- Where
- 9 sites in United States
- Volunteers
- 28 people
- Sponsor
- H. Lundbeck A/S
Migraine
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- COURAGE II (NCT05653986)
- Where
- United States
- Volunteers
- 391 people
- Sponsor
- AbbVie
Migraine
ADX10059 Migraine Prevention Study
Evaluation of ADX10059 to prevent migraine attacks
- Trial name
- NCT00820105
- Testing
- ADX10059
- Where
- 31 sites in Austria, Belgium and 3 more
- Volunteers
- 350 people
- Sponsor
- Addex Pharma S.A.
Migraine Disorders
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment.
- Trial name
- NCT06154070
- Testing
- DaxibotulinumtoxinA
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ki Health Partners. LLC
Migraine
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month.
- Trial name
- NCT04845178
- Testing
- ABP-450
- Where
- 62 sites in United States, Australia and 1 more
- Volunteers
- 797 people
- Sponsor
- AEON Biopharma, Inc.
Migraine, Aura
MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant
The objective of the study is to investigate the safety and effectiveness of PFO closure with the BioSTAR Septal Repair Implant System in a population of patients that have refractory migraine (with aura) and who have failed…
- Conditions
- Migraine, Aura, Patent Foramen Ovale
- Trial name
- NCT00283738
- Testing
- BioSTAR Septal Repair Implant System
- Where
- 2 sites in United States
- Volunteers
- 610 people
- Sponsor
- NMT Medical
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s)…
- Trial name
- NCT00382993
- Testing
- Combination Product (sumatriptan succinate/naproxen sodium)
- Where
- 28 sites in United States
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Migraine
Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
This non-interventional study will evaluate the efficacy of rimegepant 75 mg compared with placebo for the acute treatment of moderate or severe migraine attacks using individual participant data (IPD) from six completed…
- Trial name
- NCT07906262
- Testing
- Rimegepant
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Migraine Disorders
Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
This study is an open-label extension study to evaluate the safety, tolerability and efficacy of BOTOX® as headache prophylaxis in Chinese patients with chronic migraine who have successfully completed the double-blind study…
- Trial name
- NCT03193359
- Testing
- botulinum toxin Type A
- Sponsor
- Allergan
Migraine Headache
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
This study evaluates the non-inferiority of Cefaliv® compared to Neosaldina® in the treatment of migraine attack in two hundred and sixteen adults of both sexes with age between eighteen and sixty five years old.
- Trial name
- NCT02706015
- Where
- Brazil
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine
Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches
Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.
- Trial name
- NCT02472418
- Testing
- DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B)
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine Without Aura, Migraine With Aura
Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment.
- Trial name
- NCT03361423
- Testing
- Nerivio Migra-1 active device
- Where
- 12 sites in United States, Israel
- Volunteers
- 296 people
- Sponsor
- Theranica
Migraine Disorders
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
The study is designed to investigate the information on safety and efficacy of naratriptan tablets on Japanese subjects with migraine headache during Japanese post-marketing surveillance period.
- Trial name
- NCT01376193
- Testing
- Naratriptan
- Volunteers
- 500 people
- Sponsor
- GlaxoSmithKline
Migraine
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
This study evaluates the efficacy of eptinezumab to prevent migraine in participants with chronic migraine.
- Trial name
- Sunrise (NCT04921384)
- Testing
- Eptinezumab
- Where
- 87 sites in China, Georgia and 6 more
- Volunteers
- 981 people
- Sponsor
- H. Lundbeck A/S
Migraine With or Without Aura
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan
To determine the tolerability and efficacy of eletriptan in patients who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous clinical treatment (not a controlled trial).
- Trial name
- NCT01989936
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg
- Where
- 43 sites in Denmark, Finland and 3 more
- Volunteers
- 446 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.